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The main findings in the field of breast cancer proteomic research as well as modern strategies, technologies and methods of validation 
are reviewed. A special attention is focused on validated proteomic biomarkers of breast cancer. The data on proteomic profiling 
of stroma, tumor microenvironment, involvement of proteins in tumor progression, invasion and metastasis, and mechanisms of action 
of new generation drugs, are analyzed. The results of proteomic analysis are of high clinical importance and significantly improve 
tumor molecular profiling, stratification of patients, screening, diagnostics, and therapy of breast cancer.
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Breast cancer (BC) is a highly complex systemic 
disease with different histological forms and molecular 
subtypes. The biologic complexity of BC is determined 
by significant intratumoral heterogeneity that is char-
acterized by physiologic, morphologic, molecular, ge-
netic and epigenetic features. The development of the 
strategy for personalized approach for diagnostics and 
therapy of BC patients requires advanced knowledge 
on molecular markers of malignant transformation and 
treatment response for improvement of diagnostic tests, 
survival indexes and quality of life of the patients, and 
the de ve lopment of new generation anticancer thera-
peutics [1–3].
The studies of BC proteome are driven foremost 
by the necessity for an analysis of information accu-
mulated within the frameworks of “Human Genome” 
project at the levels of trascriptome, proteome, and 
metabolome. The relation between proteome with other 
areas of functional genomics is presented in Fig. 1 [4]. 
When immunohistochemical analysis (IHC) has been 
introduced into clinical practice as a diagnostic method, 
it became possible to study the state of specific protein 
receptors in BC patients, and, consequently, to identify 
the molecular subtypes of BC such as luminal А and В, 
basal, Her2-expressing subtype, and subtype histologi-
cally similar to normal phenotype [5, 6]. In turn, pro-
teome and interactome of the molecular BC subtypes 
are highly heterogeneous, therefore the clinical use 
of personalized therapy presupposes an identification 
of protein markers for diagnostics of BC and the disease 
prognosis. Despite the newest achievements in the field 
of genetic and histological assays, the deficit of molecu-
lar diagnostic me thods for determination of BC features 
is still evident [6].
The present review is devoted to an analysis 
of modern strategies, technologies and scientific find-
ings in proteomic research of BC.
Proteomic strategies, technologies and study 
subject. In recent years, a number of studies were di-
rected on the determination of relevant panel of protein 
markers of BC molecular subtypes matching the criteria 
for standard clinical study of patient’s biologic material 
for diagnostics, prognosis and therapy. Along with this, 
the development of protein profile and identification 
of protein biomarkers of BC in body tissues and fluids 
(classification of biomarkers [7], Fig. 2) should meet 
the requirements, in particular, for high level of repro-
ducibility in different laboratories during an analysis 
of monotypic material. In parallel with increasing bulk 
of experimental findings potentially important for clinical 
practice, there has been performed an improvement 
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of existing approaches and analytic methods for pro-
tein research and technical capabilities of equipment, 
in particular, via combination of a few simple methods 
and devices.
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fig. 2. Classification of biomarkers by their assignment and 
relation to tumor progression
Strategies. Advantages and limitations of the 
strategies for detection of cancer biomarkers are 
reviewed in detail in [8] (Fig. 3).
Biomarkers
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fig. 3. Classification of strategies for discovering BC biomarkers
The known strategies of preparing the samples 
for protein profiling, so called “bottom-up analysis” 
and “top-down analysis” are principally different 
at an initial stage of a sample treatment and are 
used in the methods based on gel-electrophoresis, 
liquid chromatography (LC) and mass spectrometry 
(MS) [9]. Bottom-up analysis requires initial enzymatic 
digestion of protein molecules into peptides with the 
use of proteases. The strategy is used in a few cases: 
firstly, for identification of proteins through peptide 
analysis with their following search in databases; 
secondly, for chemical modification of the peptides 
for quantification of peptides and proteins. Top-down 
analysis deals with intact preparations where protein 
molecules remain undamaged and undigested, and 
is used for an analysis of separate proteins or simple 
protein mixes, an analysis of protein-protein com-
plexes and target proteins, or for multiple identification 
of proteins with post-translational modifications. The 
main advantages and disadvantages of these strate-
gies are as follows [9]:
•	bottom-up analysis allows one to analyze the 
samples of high complexity, provides a set of large 
data bases, is more sensitive; however, it requires 
repeated analysis of the samples with large peptide 
variability, is limited by protein sequence coverage 
by identified peptides, is ambiguitous regarding the 
origin for redundant peptide sequences;
•	top-down analysis allows one to identify isoforms 
of proteins and study labile proteins with post-
translational modifications, improves quantification 
but has the limitations associated with precur-
sor ion charge state resulting in some problems 
in analy zing proteins with charge-state ambiguity 
and front-end separation (as far as the range of me-
thods for protein separation is limited).
Methodological instruments for the use of men-
tioned strategies are various: in proteomic studies per-
formed by bottom-up strategy, such methods as gel 
electrophoresis, affine chromatography (inclu ding 
isotope-coded affinity tags — ICAT), ion-exchange 
chromatography, reverse phase liquid chromatogra-
phy (RP-LC), Q-TOF MS, LTQ-Orbitrap MS are used, 
while top-down analysis studies exploit the methods 
of ion-exchange chromatography, RP-LC, 2D-LC, 
ESI MS, LTQ-Orbitrap MS [9]. Some methods, for 
example, RP-LC та LTQ-Orbitrap MS, could be used 
for both strategies.
Technologies. Different classifications of technolo-
gies for proteomic studies that are used for an analysis 
of tumor tissues and body fluids are known [10]. The 
methods of proteomic studies are based on the use 
of antibodies, in particular, Western blot, enzyme-linked 
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Bioinformatics Metabolomics
ResourcesResources Post-Genomic Era
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fig. 1. Interrelation of sources, technologies, and “omics” data in proteomic studies of BC
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immunosorbent assay (ELISA), IHC, tissue microarray 
(TMA), forward phase protein array (FFPA) and reverse 
phase protein array (RPPA), or these methods are not 
exploiting antibodies and are based on MS. The first 
group of methods is used for verification and validation 
of the obtained data for further use of the results in clini-
cal practice and requires an established knowledge 
of the proteins under study, while the second group 
of methods is represents the experimental platforms for 
generation of databases for identified proteins.
By the type of equipment used in the research, one 
may classify the proteomic technologies as follows: 
methods of gel electrophoresis (2D-PAGE, 2D-DIGE), 
peptide-oriented proteomics (LC combined with 
MS/MS: LC-MS/MS), the methods based on the use 
of arrays (RPPA) [7].
MS-based proteomic platforms for cancer stu-
dies and their principles of use are discussed in detail 
in [11]. To these platforms belong such methods as gel 
electrophoresis (1D-PAGE, 2D-PAGE (SDS-PAGE), 
2D-DIGE), liquid chromatography (LC/MALDI or LC/MS 
(LC-MS/MS)), 2D-LC or multidimensional protein 
identification technology (MudPIT), LC-ESI-MS, 
mass spectrometry (ion sources (ESI MS, MALDI MS, 
SELDI MS) combined with mass analyzers (Q MS, 
TOF MS, FT-ICR MS): MALDI-TOF MS, SELDI-TOF MS, 
ESI-MS/MS). By the data [11], LC-MS/MS is used 
mostly with bottom-up strategy, along with this some 
methodologies based on top-down strategy are al-
ready developed, too [12]. Also, for identification 
of new cancer biomar kers and potential therapeutic 
targets LC-MS/MS could be combined with quantita-
tive methods: ICAT-LC-MS/MS, iTRAQ-LC-MS/MS, 
SILAC-LC-MS/MS [11].
In general, modern proteomic studies often use 
gel electrophoresis and chromatography combined 
with MS. Mostly, gel electrophoresis and chromatog-
raphy are used for separation of protein mixture into 
specific fractions containing few proteins with similar 
physical and chemical characteristics. The fractions 
could be further analyzed by MS, allowing identifi-
cation of thousands of proteins per sample. During 
MS double scanning is used when information ob-
tained after first scanning is selectively used during the 
second scanning. Apart from this, complex methods 
based on combination of few sequential separations 
of the proteins with the use of elementary LC meth-
ods (for example SCX-RP-LC [13], SCX-SCX-LC [14] 
or RP-RP-LC [15]) and their identification with the se-
quential use of elementary MS methods (for example, 
LC-MS/MS [16–19]) have been applied.
Analysis of the use of strategies and technolo-
gies. An analysis of proteomic studies of BC shows 
several major directions in this field.
Firstly, it is the development of the strategies 
of preparation of protein/peptide samples top-down 
or bottom-up with or without their proteolytic digestion 
(for example, trypsinization/pepsinization) prior to the 
use of proteomic technologies. An analysis of experi-
mental studies of BC proteome at tissue level published 
in 2011–2016 has revealed that bottom-up strategy 
combined with modern technologies has been used 
more often (Table 1) due to its higher informativenes 
for identification of BC biomarkers [20]: on the one 
side, there has been revealed a trend for the use of uni-
fied bottom-up strategy, on the other side, for the use 
of both bottom-up and top-down strategies in one 
research but for different technological approaches. 
Also, there has been found a trend for minimal number 
of studies where top-down strategy was used along 
with narrow spectrum of methods (see Table 1). The 
authors [9] have listed wider spectrum of methods 
with which top-down strategy could be used for protein 
identification, but by our consideration, methodological 
variability of top-down in proteomic BC research is some 
what depleted (see Table 1). This fact opens possibili-
ties for analyzing the limitations of methods and equip-
ment to overcome them for the proper use of top-down 
strategy for the analysis of complex protein mixtures and 
for the development of the optimal protocols on the use 
of this strategy with other methods and/or new technical 
solutions. An example of such optimization for the use 
of top-down is the work [20], reporting on successful 
usage of 2D-LC-MS/MS for identification of BC proteins 
in tumor tissue (see Table 1).
The second direction is the development of tech-
nologies via combination of several methods (chroma-
tography and tandem MS). An analysis of experimental 
studies on BC proteomics from the point of applied 
technologies has revealed a trend for the widest use 
of combined LC-MS/MS with different modifications 
(see Table 1), where among elementary methods most 
commonly RP-LC, ESI MS (ion source) and LTQ-Orbitrap 
MS (tandem hybrid mass analyzer) were being used. For 
analysis of BC proteome triple mass analyzer XCT II MS 
(Triple Q MS) is used as well [21] (see Table 1). In the 
proteomic studies of different biologic material there ap-
pears a trend for the combined use of different elemen-
tary LC methods (SCX-RP-LC [13]), while in the studies 
of total BC proteome such trend is not observed — similar 
LC methods are used in tandem (SCX-SCX-LC [14] and 
RP-RP-LC [15]) (see Table 1). There is also a trend for 
prevalent use of label-free combined LC-MS/MS me-
thods (label-free analysis, Table 1), that opens the pos-
sibilities for active use of methods utilizing affine labels 
(label analysis, Table 1) to achieve better quality of the 
results. In general, in proteomic studies employing MS, 
a wide spectrum of ion sources and mass analyzers has 
been used combination of which depended on the aim 
of the research. The use of one or another elementary 
methods was analyzed only for the studies where the 
methodological components were described in detail 
(see Table 1).
It is necessary to note that there have been repor-
ted methodologies, in particular, combination of both 
strategies to obtain maximally informative protein profile 
of the tumors [20], modification of the stage of peptide 
preparation for LC-MS/MS with analytical instruments 
in silico [19], development of new proteomic approach 
on the use of affine chromatography with top-down 
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strategy [22], development of protocol for the use 
of LC-MS/MS with isotope dilution [23]. One should be-
lieve that along with the development of new proteomic 
analytical technologies for protein identification and 
achievement of the data on protein post-translational 
modifications there will be a drastic increase of the 
number of identified cancer biomarkers, including bio-
markers of BC progression. For their further implication 
into clinical practice, an additional validation of identified 
proteins using the antibody-based methods is required, 
that, in turn, will stimulate the study of properties and 
functions of these proteins.
At present time proteomic-based search of BC bio-
markers has a number of limitations at different levels:
•	Biologic material. Molecular heterogeneity of BC, 
complex composition of biologic fluids used as ex-
perimental samples, multiplicity of proteome com-
position and its dynamical variability create sig-
nificant methodological challenge in proteomic 
research [24].
•	Isolation, storage and preparation of experimental 
samples. Requirements for conditions of sample 
collection, their primary treatment, high quality 
storage conditions of biologic materials are being 
solved by standardization that is determined in part 
by special conditions preventing degradation of the 
particular proteins. There are some achievements 
in the standardization of plasma samples collection 
for obtaining plasma proteomic profile [21].
Disadvantages of bottom-up and top-down strat-
egies could be referred to such limitations as well. 
Presently they are counter-balanced by technical 
solution for combination of the strategies in a joint 
method for proteomic profiling [20]. Apart from this, 
for tumor peptidome analysis an improved protocol 
of peptide preparation has been proposed that, being 
combined with the methods in silico, completes the 
results of bottom-up strategy [19].
There are still none technical means allowing si-
multaneous isolation and analysis of DNA, RNA and 
proteins from cryomaterials [24].
•	Devices and instruments. In the samples low 
quantities of proteins that hypothetically could 
be tumor-specific, require perfect analytical 
sensitivity of the equipment. The methods of gel-
electrophoresis are of the lowest sensitivity while 
the MS-based methods are of the highest sensi-
tivity. MS possess own limitations as well at the 
levels of ion sources and mass analyzers, making 
impact into general disadvantages of combined 
elementary methods (for example, if ion sources 
MALDI MS or SELDI MS are combined with analyzers 
TOF MS — MALDI-TOF MS, SELDI-TOF MS [4]).
•	Limitations in silico. The software (SW) used for as-
sessment of experimental data at the stages of their 
analysis, visualization, storage, and interpretation 
should be up-graded or developed de novo [24]. 
Presently SW is used more and more often for 
verification and validation of the data [19, 20, 25]. 
The progress in silico will allow reaching higher 
levels of BC research [24], meta-analysis [24] and 
assessment of the obtained data.
Objects of study. The wide spectrum of human 
biologic material used for proteomic study of BC, al-
lows one to perform systemic analysis of tumor-host 
interactions. For sampling tumor tissue, invasive me-
thods are used. Body fluids could be taken by noninva-
sive methods that is much more preferable for clinical 
application of experimental results.
In proteomic study of BC, a large number of mono-
typic samples are being used. Protein fractions are 
isolated from tumor or normal cells, tissues and 
body fluids [5, 7, 11, 26–33]. Biopsy, postoperative 
material, tissue obtained by laser capture microdis-
section (LCM) method [34, 35], BC cell lines in vitro, 
experimental tumors in vivo are studied in tumor tissue 
Table 1. Methods for modern proteomic strategies applied 
in the proteome research of BC
Bottom-up Top-down Bottom-up +  top-down
Label-free analysis
LC-MS/MS:
LC-MS/MS [16, 17, 21, 25, 29, 
33, 36, 43–45, 79],
LC-MS/MS with isotope 
dilution [23],
nLC-MS/MS [18, 28, 41],
2D-LC-MS/MS [15, 22];
basic methods of liquid  
chromatography for LC-MS/MS:
RP-LC [21, 29, 36],
2D-LC (RP-RP-LC) [15];
basic methods of mass spectrom-
etry for LC-MS/MS (ion sources):
ESI MS [21, 22, 29, 25],
SELDI MS [44];
basic methods of mass  
spectro metry for LC-MS/MS 
(mass analyzers):
Q MS [17],
Q-TOF MS [28],
LTQ MS [16, 45, 79],
hybrid Q-Orbitrap MS [33, 43],
LTQ-Orbitrap MS [15, 18, 22, 29, 
33, 36, 41],
XCT II MS (TripleQ MS) [21];
reaction monitoring mass  
spectrometry:
SRM-MS [23],
MRM-MS [14, 21].
Label analysis
label-LC-MS/MS:
SILAC-LC-MS/MS [25],
iTRAQ-2D-LC-MS/MS [37],
iTRAQ-MD-LC-MS/MS [14];
basic methods of LC  
for label-LC-MS/MS:
SAX-LC [25],
MD-LC (SCX-SCX-LC) [14];
basic methods of mass  
spectrometry for label-LC-MS/MS 
(ion sources):
MALDI MS [14];
basic methods of mass  
spectrometry for label-LC-MS/MS  
(mass analyzers):
TOF-TOF MS [14];
label-reaction monitoring mass 
spectrometry:
mTRAQ-SRM MS [37]
1D-PAGE
(SDS-PAGE) [18],
2D-PAGE
(SDS-PAGE)
[14, 22, 28, 37, 46],
2D-DIGE [14, 36],
affinity chroma-
tography [22]
Label-free  
ana lysis
2D-LC-MS/MS 
[20]; 
basic methods 
of 2D-LC-MS/MS:
Bottom-up  
Proteomics:  
Nanospray MS,
TripleTOF MS
[20];
Top-Down  
Proteomics:
RP-LC,  
Nanospray MS, 
Orbitrap MS
[20]
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proteomics. In the research of body fluids, postopera-
tive serum, tumor extracellular fluid, blood serum and 
blood plasma, mononuclear cells, cerebrospinal fluid, 
urine, saliva, milk, nipple aspirate, fluids from organs 
and body cavities are used. A typical scheme of mo-
dern proteomic studies of BC is reviewed in details 
in [7], and illustrated in Fig. 4.
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Discovery driven Knowlege based
FPPA
RPPA
MS imaging
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fig. 4. Schematic representation of proteomic BC studies
Clinical importance of the results of proteomic 
studies of BC. Proteomic profiling of biologic ma-
terial from BC patients with the use of MS-based 
methods allows detecting simultaneously much more 
individual proteins than antibody-based methods (in-
cluding IHC [33]) applied for verification and validation 
of the results. Information obtained from proteomic 
analysis is useful for studying the role of extracellular 
matrix [15]; post-translational modification of pro-
teins [31, 36]; proteins involved in DNA repair [33]; 
tumor micronvironment [33]; microenvironment 
of tumor cell [22]; proteins of tumor stroma [37, 38]; 
cytoplasmic proteins [39]; proteins of endoplasmic re-
ticulum (EPR) [40]; the role of proteins of mechanistic 
pathways, components of protein biosynthesis, cyclins 
in progression, invasion and metastasis of BC [38].
The proteomic profiling based search for BC bio-
markers showed following trends: BC progression 
(BC with different lymph nods status [37, 41, 42] and 
metastatic BC [29, 31, 35]), profiling of BC subtypes 
(triple negative breast cancer (TNBC) [25, 37, 38, 41, 
43, 44], HER2+ [14, 25, 37, 38, 44, 45], ER/PR [25, 
37, 38], basal and luminal [19, 20, 45]) and the study 
of tumors of different histopathological grade [22, 27].
In [46], the top-down strategy for 2D-PAGE 
(SDS-PAGE) and Bradford technique have been used 
for determination of expression levels of proteins in tu-
mor and normal tissues of mammary gland. In total, 
454 proteins have been found, 138 of which showed 
an altered expression in tumor tissue (expression 
of 61 proteins was suppressed, 3 — up-regulated, and 
74 — down-regulated). So, compared to normal tissue, 
expression of a large number of proteins is changed, 
and many of them are down-regulated, sometimes 
completely suppressed [46]. In our view, these data 
should have been verified by MS and LC-MS, because 
of low separating capacity of 2D-PAGE (SDS-PAGE).
Generation of large databases for proteomic 
profiles of biologic materials has limitations caused 
by variability of both the sample collection and pro-
teomic technologies used for analysis. In [21], the 
collection of plasma samples from healthy individuals 
and BC patients has been standardized that allowed 
one to create database of proteomic profiles of plasma 
with the use of bottom-up strategy and combined 
LC-MS/MS method. This database will be useful for 
the search of BC biomarkers for diagnostic, prog-
nosis, monitoring of the disease progression and 
therapy [21]. The data on three proteins — potential 
BC biomarkers, have been already verified (Table 2).
The recent findings in BC proteomic analysis 
pertaining to screening, diagnostics, therapy and 
prognosis are reviewed in detail in separate sections 
presented below.
Screening. Screening tests require high sensi-
tivity, specificity, accuracy, non-invasiveness, ease 
of process, low cost and reliability of false-positive/
false-negative result, therefore proteomic analysis 
of biologic body fluids for identification of markers 
for preclinical changes could be the best choice for 
screening purposes.
Using combined LC-MS/MS and bottom-up strategy, 
protein biomarkers were identified in urine of BC patients 
with different disease stage and tumor material was stud-
ied in parallel as well [29]. Expression levels of 59 proteins 
was found to be different from that in control samples, 
in particular, 13 novel up-regulated proteins associated 
with BC of diagnostic value have been revealed. The 
relation between BC progression and a panel of specific 
protein markers has been ascertained: preinvasive ductal 
carcinoma in-situ — leucine LRC36, protein MAST4 and 
uncharacterized protein CI131, early invasive BC — 
DYH8, HBA, PEPA, MMRN2 proteins, filaggrin, and un-
characterized protein C4orf14 (CD014), and metastatic 
BC — AGRIN, NEGR1, FIBA proteins and KIC10 keratin. 
The proteins that have been already validated are listed 
in Table 2. These data will be used for the development 
of screening programs.
Diagnostics. Early diagnosis and monitoring 
of BC progression are of great importance for better 
prognosis of the disease.
TNBC is a heterogeneous pathology with unfavor-
able prognosis due to insufficient targeted treatment 
effectiveness. For the first time proteomic analysis 
of 12 000 proteins and molecular profile of this BC sub-
type in tumor samples and cell cultures in vitro was 
provided using combined LC-MS/MS and bottom-
up strategy [43]. In this research proteins of signal 
pathways were quantified and proteins markers of drug 
resistance were identified. These data could be useful 
for understanding the mechanisms of drug resistance, 
as well as for diagnosis and therapy of TNBC.
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Table 2. The results of modern proteomic studies of BC
Biological samples Research methods Methods of validation Protein(s) Field of use Ref.
Invasive 
object
Tumor tissue of invasive duc-
tal carcinoma
Subtypes:
Luminal B HER2+ve
HER2 enriched
2D-PAGE (SDS-PAGE), 
2D-DIGE,  
iTRAQ-MD-LC-MS/MS 
(MD-LC (SCX-LC),  
MALDI-TOF/TOF MS)
Western blotting 
MRM-MS
Apolipoprotein A1 (APOA1)
Gelsolin (GELS);
Heat shock protein HSP 90-beta 
(hs90b);
Eukaryotic elongation factor 
1 alpha (EF1A1); Peroxiredoxin 
3 (PRDX3); NHRF1.
Peroxiredoxin 1 (PRDX1); Oxidore-
ductase (catD); Calreticulin (CALR)
ATPase beta chain (atpB); 
SOX14 (CH60) SRY-box 14.
Protein biomarkers of BC
Tumor subtyping, diagnosis 
of early and late stages
Prediction of treatment out-
come
[14]
Tumor tissue of invasive duc-
tal carcinoma
Stages:
Early stages
Late stages
2D-PAGE (SDS-PAGE), 
2D-DIGE,  
iTRAQ-MD-LC-MS/MS 
(MD-LC (SCX-LC),  
MALDI-TOF/TOF MS)
Western blotting 
MRM-MS
Tropomyosin 4 (TPM4); Oxido-
reductase (catD); Peroxiredoxin 
3 (PRDX3); Annexin A3 (ANXA3);
Heat shock protein family B (small) 
member 1 (HSPB1).
Calreticulin (CALR); Ovotransferrin-
like (TRFE); Gelsolin (GELS);
SOX14 (CH60) SRY-box 14;
Capping actin protein, gelsolin like 
(CAPG);
Ywhag (1433G) tyrosine 3-mono-
oxygenase/tryptophan 5-monooxy-
genase activation protein gamma;
Glucose regulated protein 
78 (grp78);
NHRF1.
Protein biomarkers of BC
Tumor subtyping,
diagnosis of early and late 
stages
Prediction of treatment out-
come
[14]
Lymph node positive vs. 
negative, low grade primary 
BC tissues
Primary breast carcinoma tis-
sues from patients with dif-
ferent lymph node status
2D-PAGE (SDS-PAGE)
iTRAQ-2D-LC-MS/MS
qPCR (transcript level), 
iTRAQ-2D-LC-MS/MS, 
mTRAQ-SRM MS,  
IHC/TMA;
mTRAQ-SRM MS, 
IHC/TMA
Transgelin (TAGLN)
Transgelin (TAGLN);  
Transgelin-2 (TAGLN2)
Cancer-associated biomark-
ers of lymph node metasta-
sis of BC
Cancer-associated biomarkers 
of lymph node metastasis of BC
[37]
[37]
Breast ductal carcinoma tis-
sues
Published data and data-
base (mRNA level)
IHC/TMA Kinesin associated protein 3  
(KIFAP3)
Biomarker of BC [39]
Metastatic BC (tumor tissue) Published data and data-
base (mRNA level)
IHC/TMA Ribosome binding protein 
1 (RRBP1)
Biomarker of invasive breast 
carcinomas
[40]
Breast tumor tissues HER2+ 
TNBC
LC-MS/MS (SELDI MS) IHC KRT19 (CK19) keratin 19.
RNA-binding Ras-GAP SH3 bind-
ing protein (G3BP)
Biomarker of HER2+ tumors;
Predictive biomarker of TNBC;
Biomarker correlating with tu-
mor progression, and me-
tastasis
[44]
Human disease-free breast 
tissues and malignant breast 
tumors
LC-MS/MS with isotope 
dilution
SRM-MS Apurinic/apyrimidinic endonucle-
ase 1(APE1)
Development of APE1 inhibi-
tors as anticancer drugs;
may have prognostic and pre-
dictive significance in cancer 
treatment
[23]
BC tissues with different ER, 
PR and HER2 status (meta-
analysis)
Published data on pro-
teins as important tar-
gets and proteomic pro-
cesses in BC
RPPA ER; PR; Apoptosis regula-
tor (BCL2); GATA binding pro-
tein 3 (GATA3);
KIAA1324 (EIG121); Epidermal 
growth factor receptor (EGFR);
Erb–b2 receptor tyrosine ki-
nase 2 (HER2); HER2p1248;
Cyclin B1 (CCNB1);
Cyclin E1 (CCNE1).
10-protein biomarker panel 
for BC classification and out-
comes prediction
[38]
Non-in-
vasive 
object
Serum (patients with recurrent 
BC and patients with no sign 
of recurrence 5 years after di-
agnosis)
Lectin affinity chroma-
tography, 2D-DIGE,  
LC-MS/MS (RP-LC)
ELISA CDH5 (CADHERIN5) cadherin 5, 
type 2 (vascular endothelium)
Predictive and diagnostic bio-
marker
[36]
Plasma (healthy donors and 
BC patients)
LC-MS/MS  
(RP-LC, ESI MS, 
XCT II MS (TripleQ MS)
MRM-MS Apolipoprotein A1 (APOA1);
Hemopexin hemopexin-like;
Angiotensin preprotein.
Candidate biomarkers of BC [21]
Com-
bined 
object
Urine and tumor tissue (iden-
tification)
Cell lines (validation)
Tumor tissue (validation)
LC-MS/MS (RP-LC)
Western blotting
IHC, Western blotting
Extracellular matrix pro-
tein 1 (ECM1);
FLG2 (FILAGGRIN) filaggrin fami-
ly member 2; Microtubule associ-
ated serine/threonine kinase family 
member 4 (MAST4);
Microtubule associated serine/
threonine kinase family mem-
ber 4 (MAST4).
Screening, monitoring of tumor 
progression
[29]
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Variability of HER2/Neu overexpression is typical 
for molecular subtypes of invasive ductal carcinoma, 
luminal B HER2+ (ER+/PR+/HER2+) and HER2 enriched 
(ER−/PR−/HER2+), which are poorly studied yet in re-
gard to prognostic markers. A comparative proteomic 
profiling of luminal B HER2+ve and HER2 enriched sub-
types of invasive ductal carcinoma and healthy tissues 
of mammary gland was provided [14]. Tumor material 
obtained during modified radical mastectomy has been 
used for the search of protein biomarkers of early and 
late stages of these molecular BC subtypes with the use 
of proteomic analysis methods (see Table 2). Top-down 
strategy was used for gel-electrophoresis, and bottom-
up strategy — for MS-based methods. In total, in the 
studied BC subtypes 67 proteins expressed in tumor 
material were found, and expression of 68 proteins 
depended on BC stages; there have been validated 
(see Table 2) 6 proteins for luminal В HER2+ subtype, 
5 proteins for HER2+ subtype, 5 and 8 proteins for early 
and late stages of these BC subtypes, respectively. The 
authors believe that these panels of protein biomark-
ers could be used for molecular classification of the 
tumors in diagnostics of early and late BC stages and 
for prognosis of treatment outcome.
Several studies analyzed expression of protein 
isoforms and proteins which composition and func-
tions were altered via post-translational modifica-
tions (phosphorylation, acetylation, glycosylation, 
methylation and ubiquitination) [11, 31, 36]. The 
results obtained are proposed for the use as sensitive 
diagnostic markers of BC clinical course. In studies 
mentioned above, the samples of blood serum and 
urine of BC patients and paraffin blocks of primary 
tumors (FFPE), were analyzed by lectin microarray 
[31] or gel-electrophoresis as top-down strategy com-
bined with MS-based methods as bottom-up strategy 
[36] (see Table 2). As it has been concluded [31, 
36], the altered glycosylation of proteins in cancer 
patients could be associated with particular cancer 
types, however, total spectrum of glycane structures 
is still unknown. An analysis of glycosylated proteins 
of blood serum and urine of patients with metastatic 
BC has revealed diagnostic and predictive potential 
of cadherin-5 and lectin-binding patterns, including 
N- and O-bound glycanes [31, 36]. This is supported 
by validation of the results [36] establishing 90% speci-
ficity of cadherin-5 as diagnostic marker of metastasis 
(see Table 2).
Therapy. Proteomic profiling of BC specimens 
could be also useful for analyzing mechanism 
of action of anticancer agents such as identification 
of targets [25, 44], search for protein-targets or their 
inhibitors for adjuvant chemotherapy [23, 41] and 
controlling invasive properties of tumors via influence 
on proteins of the cells surrounding tumors [33].
In regard to the recent results of integrated “ge-
nome-transcriptome” studies in the absence of uni-
versal panel of BC biomarkers and optimal medicinal 
remedies the proteomic analysis of tumor tissues 
of different BC subtypes is of special importance. 
Using bottom-up strategy, quantification technology 
SILAC-LC-MS/MS and LC-MS/MS on FFPE BC tissue 
blocks (ER+/PR+, HER2+, TNBC) and BC cell lines 
(HCC1599, MCF7, HCC1937) the study of functional 
networks between multifunctional proteins and cell 
processes in the tumors of different molecular sub-
types has been conducted [25]. Up to 410,000 pro-
teins have been analyzed, and it has been shown 
that BC subtypes differ in the functions of proteins 
involved in translation of mRNA, cell growth, intercel-
lular interaction, and energetic metabolism. In total, 
19 protein signatures were found, just 3 from which 
were related to gene copy number, and 11 — to mRNA 
levels. Possibly, these data could support an absence 
of regular relations between the protein product level 
and gene copy number, and protein product content 
and mRNA profile. The special SW was applied for 
a cross-validation procedure of the obtained data 
on proteomic profiling of the tumors. These results 
embody the novel ideas that are practically valid for 
the development of specific therapeutic agents.
Predictive protein markers of different BC sub-
types will allow us to determine therapeutic response 
to particular treatment, to optimize and personalize 
cancer therapy.
In a pilot study [44], protein signatures of two 
BC subtypes potentially useful for prediction of treat-
ment results were identified. Specific predictive protein 
markers of response to neoadjuvant chemotherapy 
were studied using bottom-up strategy and combined 
LC-MS/MS method in tumors of HER2+ and TNBC 
subtypes. There were identified 20 protein signatures 
typical for tumors of both subtypes, 20 signatures 
with different expression levels allowing to classify 
these subtypes, 20 predictive markers of response 
to neoadjuvant chemotherapy for HER2+ subtype 
and 30 predictive markers of response to neoadjuvant 
chemotherapy for TNBC subtype. TNBC subtype was 
characterized by overexpression of ALDH1A1 and 
galectin-3-binding protein, while in HER2+ subtype 
the following proteins were found to be overexpressed: 
transketolase, transferrin, CK19, thymosin β4, and thy-
mosin β10. The number of proteins, namely, enolase, 
peroxiredoxin 5, periostin precursor, cathepsin 
D preproprotein, vimentin, Hsp 70, annexin 1, RhoA 
were related to the tumor response to neoadjuvant 
chemotherapy. Also, two proteins for classification 
of these subtypes were validated (see Table 2).
In spite of constantly increasing number of clinical 
trials of anticancer agents there is a necessity for the 
correction of modern treatment schemes from the 
point of benefit/risk ratio. As far as TNBC is highly 
aggressive and there are still none sensitive spe-
cific prognostic markers, up-to-date an optimal target 
therapy of this subtype isn’t developed. As a rule, the 
patients with negative lymph node status are cured with 
adjuvant chemotherapy, but in 30% of cases distant 
metastasis develops [47, 48]. With the use of bottom-
up strategy and technology nLC-MS/MS [41] in tumor 
material of patients with TNBC and negative lymph 
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node status not treated with adjuvant chemotherapy, 
11 prognostic protein signatures, protein products 
of the CMPK1, AIFM1, FTH1, MTHFD1, EML4, GANAB, 
CTNNA1, AP1G1, STX12, AP1M1, CAPZB genes were 
identified and verified. The obtained results could 
be useful in clinical practice and address an expedi-
ency of adjuvant systemic therapy in patients with 
TNBC and negative lymph node status.
The search for a candidate for proteomic biomarker 
for prognosis and therapy of BC patients has been re-
cently attempted [23]. Overexpression of APE1З (the 
main protein of DNA excision repair pathway apurinic/
apyrimidinic endonuclease) was detected in clinical 
material with the use of bottom-up strategy and the 
deve loped analytical approach based on MS [23] (see 
Table 2). Hyper-/hypoexpression of APE1 could be pos-
sibly related to decreased/increased tumor cell survival 
rate, therefore in future its inhibitors could be used 
in clinical practice [23]. It is supposed that APE1 expres-
sion levels could be related to life expectancy of BC pa-
tients, and clinical assessment of APE1 expression 
levels in intact and tumor tissues of mammary gland 
could be of prognostic and predictive value [23].
Cancer-associated fibroblasts (CAFs) are known 
to stimulate angiogenesis and metastasis [49, 50] and 
an inflammatory and wound healing related activation 
of fibroblasts are the main mechanisms of CAF activation 
[33]. The functional state of CAFs was assessed in bi-
opsy specimens of breast adenocarcinoma using com-
bined method LC-MS/MS and bottom-up strategy [33]. 
In total, 2074 proteins from biopsy material fibroblasts 
and 5212 proteins from cultured ZR-75-1 cells were 
identified. Comparative analysis of proteins of untreated 
fibroblasts, fibroblasts incubated with IL-1β (in vitro 
modeling of inflammatory way of fibroblast activation) 
or TGF-β (in vitro modeling of wound healing-induced 
activation of fibroblasts) has shown that proteomic pro-
file of BC biopsy could be useful for assessment of cell 
types at quiescent state, inflammation, wound healing. 
Proteomic profile of CAFs was found to be close to that 
of fibroblasts at the state of wound healing (common 
proteins, including fibulin-5, SLC2A1 and MUC18). 
The authors supposed [33] model CAFs systems could 
be advantageous for testing the agents which inhibit 
or reverse the proinvasive activity of the components 
of tumor microenvironment.
Prognosis. At present time the existing clini-
cal criteria of pathologic process based on tumor 
aggressiveness grading don’t reflect a real state 
of cancer process for assessment of its progression 
and prognosis [22]. With the use of top-down strat-
egy (me thods: affinity chromatography, 2D-PAGE 
(SDS-PAGE)) and bottom-up strategy (combined 
method LC-MS/MS) [22] protein signatures associ-
ated with histopathological grading (G1, G2, G3) 
of breast tumors were indentified, 49 of which were 
validated using the data of meta-analysis of transcrip-
tion profiling of tumors of independent group of pa-
tients. The special SW permitted to determine that the 
validated proteins are localized in intercellular space, 
plasma membrane, cytoplasm, and nuclei. The ob-
tained results could be important for the revision of the 
microenvironment model during tumor progression 
and be useful for classification and prognosis of BC.
Two proteins, transgelin and transgelin-2 could 
be of clinical importance serving as prognostic pro-
teomic markers of metastasis of different tumor types 
(pancreatic, colorectal, gastric, lung, BC) [37, 51–54]. 
Transgelin is a differentiation marker of smooth mus-
cles [55], and is expressed in myofibroblasts and CAFs 
of gastric and lung tumors [54, 56]. Its up-regulation 
in fibroblasts in gastric tumor tissue supports tumor 
cell migration and invasion via increased production 
of matrix metalloproteinase-2 [52], and this protein 
is oncosuppressor, expression of which is down-
regulated by Ras oncoprotein in BC samples [57]. 
Hypermethylatioin of its promoter is related to down-
regulation of its expression in cell lines and tumor 
tissues of mammary gland [58]. In regard to transge-
lin-2, its overexpression in breast tumor vasculature 
has been reported [59]. Using proteomics methods, 
a comparative analysis of expression of transgelin and 
transgelin-2 in lymph nodes of BC patients has been 
provided [37]. Using top-down strategy and 2D-PAGE 
(SDS-PAGE) up-regulation of transgelin in positive 
lymph nodes of BC patients with primary low grade 
tumors and different lymph node status has been re-
vealed (see Table 2). These results were clinically vali-
dated on the larger group of BC patients with different 
lymph node status (see Table 2). In this research [37], 
a comparative proteomic analysis of transgelin and 
transgelin-2 in tumor tissue of BC patients with the 
use of bottom-up strategy demonstrated a specific 
relation between transgelin and lymph node metas-
tasis in BC patients and tumor differentiation grade, 
nevertheless no association of transgelin expression 
with molecular markers ER, PR, HER2 has been found. 
Since both presence [60] and absence [37] of specific 
expression of transgelin have been reported, its speci-
ficity as a marker is under question. Down-regulation 
of transgelin in high grade tumors and overexpres-
sion of transgelin-2 in metastatic and low differenti-
ated tumors were considered as a consequence 
of stromal cells dedifferentiation [37]. It has been 
shown (IHC/TMA) that transgelin is mostly expressed 
in stromal cells (fibroblasts and endothelial cells), 
while transgelin-2 is expressed in epithelial cells of the 
tumors [37, 56]. The authors [37, 56] supposed that 
tumor stroma is capable to express relevant proteomic 
biomarkers of potential clinical importance.
The studies on gene expression profiling have 
created large databases for genes, RNA and proteins 
expressed in BC. In particular, in tumor samples 
of BC patients and cell lines [61] overexpression 
of KIFAP3 gene (located in 1q24 chromosome loci, 
and coding for kinesin associated protein 3 (KIFAP3) 
has been revealed [39]. Protein KIFAP3 is localized 
in nucleus, cytoplasm and EPR [62, 63] and interacts 
with the proteins involved in carcinogenesis: interac-
tion of KIFAP3 with APC affects cell migration [64, 
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65], KIFAP3 is phosphorylated with BRK or PTK6 ki-
nases in BC cell line BT20 [66], KIFAP3 is required for 
BRK-induced cell migration [66] and may play a role 
of a key effector of BRK signal pathway [66]. Experi-
mental study on validation of KIFAP3 protein [39] (see 
Table 2) has shown its overexpression in the cells 
of breast ductal carcinoma, mostly in cytoplasm. 
Expression of one more protein considered as BC-
associated markers, namely RRBP1 (ribosome binding 
protein), was studied [40]. RRBP1 is a multifunctional 
membrane protein localized in rough EPR [67–69], 
cytoplasm and nucleus [70], participating in trans-
location of nascent proteins through the membrane 
of rough EPR [71]. RRBP1 interacts with KIF5B [72] 
and is involved in ribosome binding [71], biosynthesis 
of procollagen and terminal differentiation of secretory 
tissues [67, 73]. High level of its expression was found 
in some cancer cell lines [74], and its overexpression 
was registered in colorectal cancer [75]. Overexpres-
sion of RRBP1 in the perinuclear region of cytoplasma 
was documented in 84% (177/219) cases of breast 
carcinoma [40] (see Table 2). These two examples 
demonstrate an integrated interaction between the 
data and sources of “omics” and systemic assessment 
of functions of BC-associated proteins.
Systemic neoadjuvant therapy may increase the 
risk of recurrence after organ-sparing operations and 
promote the development of drug resistance [76–78]. 
Modern functional proteomics could be helpful for 
prognosis of pathologic response to systemic neoad-
juvant therapy. Proteomic meta-analysis utilizing RPPA 
method covering tumor specimens from 712 BC pa-
tients who received taxane and anthracycline-taxane 
systemic therapy, has validated a panel from 10 pre-
dictive biomarkers (see Table 2) [38]. Based on these 
findings, the patients may be stratified into 6 prognos-
tic groups: HER2+; ER–/PR– and ER–/PR–/HER2 with 
unfavorable prognosis; ER+/PR+ with favorable 
prognosis; and three intermediate groups that mostly 
were characterized by overexpression of tumor cell 
proteins involved in various cell processes (cyclines, 
components of protein biosynthesis system, stromal 
markers, proteins of mechanistic pathways).
For better stratification of the patients at the stage 
of prescription of adjuvant chemotherapy and for prog-
nosis of the disease course in the study [42] the blood 
serum samples of patients with primary BC and lymph 
node metastases have been analyzed postoperatively. 
With the use of ion-exchange and affine chromato-
graphy (immobilized metal affinity chromatography — 
IMAC) combined with SELDI-TOF MS protein profil-
ing and MALDI-TOF/TOF MS for peptide profiling 
4 mass peaks were revealed (m/z 3073, m/z 3274, 
m/z 4405 and m/z 7973) believed typical of proteins 
associated with recurrence-free survival of the pa-
tients. Among these potential biomarkers, a protein 
with m/z 3274 was identified as an inter-alpha-trypsin 
inhibitor heavy chain 4 fragment. These data should 
be further validated with enrollment of an independent 
group of patients, however, the authors consider the 
use of anion-exchange fractionation combined with 
SELDI-TOF MS as a promising tool for identification 
of new prognostic markers of BC [42].
Improvement of quality of prteomic BC stu dies. 
The studies of BC proteome and peptidome aimed 
at the search of diagnostic and prognostic markers 
develop dynamically, especially in regard to vali-
dated clinical results. Such aim requires perfection 
of methodological and technical approaches for the 
analysis and identification of various BC biomarkers. 
As an example of the newest approaches one could 
mention combining existing strategies and developing 
new analytical platforms.
Combined strategies. A large number of works re-
viewed in [9] addressed advantages and disadvantages 
of bottom-up and top-down strategies for different 
tasks, and also expediency of their use for proteomic 
analysis and quantification of protein molecules.
In the study [20], the complementarity of these 
strategies was assessed with the use of combined 
method LC-MS/MS and material of two BC models, 
namely, patient-derived xenografts established from 
a basal-like and luminal B BC subtypes. The study 
has been designed as follows: testing of label-free 
top-down quantitative proteomics platform (as far 
as LC-MS/MS is used mostly with bottom-up strat-
egy); comparative analysis of differential expression 
of proteins and their proteoforms with low molecular 
weight (< 30 kDa) in the samples of basal and luminal 
B molecular BC subtypes. The comparative analysis 
of the efficacy of using bottom-up and top-down 
strategies supported the 10-fold superiority of bottom-
up: identification of 49,185 groups of peptides and 
quantification of 3519 proteins derived from them 
versus 982 proteoforms and 358 proteins in the case 
of top-down use. However, quantitative effective-
ness of the strategies had a ratio of 60:40, and the 
use of top-down allowed to gain a unique informa-
tion complementing the data obtained with the use 
of bottom-up. In turn, bottom-up was by 8 times more 
accurate for identification of proteins with molecular 
weight of 0–30 kDa. With the use of special SW, the 
obtained data were validated. This work demonstrated 
the priority of combination of these strategies in the 
study of BC proteome and BC biology involving ge-
nome data, and also confirmed that bottom-up strat-
egy does not allow identifying the differences between 
some post-translational modifications (for example, 
phosphorylation).
New analytic platform. Tumor peptidome (intra-
cellular and intercellular products of protein degrada-
tion) could represent a potential source of biomark-
ers for tumor-related proteolytic properties. Using 
combined method LC-MS/MS, an analytic platform 
in silico has been developed which along with im-
proved protocol of peptides isolation complemented 
the results of conventional bottom-up strategy. This 
platform has been used for a complex analysis of pep-
tidome of ovarian cancer and xenografts of basal and 
luminal BC subtypes [19]. The developed platform 
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represents the novel technological stage for further 
determination of molecular features and functional 
significance of peptidomic/degradomic activities 
in tumor tissues. It is characterized by reproducibility 
of the results and high capacity of studies on quantifi-
cation of identified peptides. The use of the platform 
allowed one to identify peptidome profiles reflecting 
the types of action of tumor-associated proteases; 
the results were validated with the use of special 
SW. The developed analytic platform and the obtained 
data are of practical significance not only for tumor 
tissue profiling in BC, but also in other cancer types 
as far as aberrant degradation of proteins is inherent 
to many of tumor types.
Methods for verification and validation of the 
results of proteomic analysis. Verification and 
validation of the results of experimental studies are 
the mandatory stages is analyzing the bulk of findings 
based on the generally accepted methods. Validation 
means that from the pool of identified proteins only 
relevant oncological markers of clinical significance 
should be selected. Three groups of methods each 
with its advantages and disadvantages, are being 
used for this purpose: IHC based, TMA based, and 
MS based (SRM/MRM-MS) [7]. Combined IHC/TMA 
group of validation methods is becoming more and 
more popular [37, 39, 40], because it allows to ana-
lyze the samples of tissues of larger size compared 
to convenient TMA [7]. Common methods are 
Western blot [14, 29] and MRM-MS [14, 21] while 
SRM-MS [23], mTRAQ-SRM MS [37], IHC [44], 
RPPA [38] and ELISA are less commonly used [36]. 
There is a trend for the use of several validation meth-
ods in one study for more effective assessment of the 
significance of the obtained results (Western blot + 
MRM-MS [14], mTRAQ-SRM MS + IHC/TMA [37], 
Western blot + IHC [29], Table 2). It’s necessary 
to note that RPPA has been used as the validation 
method in proteomic meta-analysis of BC tissue 
(n = 712) aimed at determination of predictive bio-
markers panel ([38], Table 2). The use of SW for verifi-
cation and validation of experimental results becomes 
more common [19, 20, 25]. The results of proteomic 
studies which were successfully validated are used 
as clinically valid biomarkers for diagnostics, prog-
nosis and therapy of BC [29, 36–40, 44].
In conclusion, an analysis of literature sources 
on BC proteomics indicated an important role of top-
down and bottom-up strategies as the major ones 
in the search of proteomic BC biomarkers with the use 
of LC-MS/MS. The technological progress is focused 
on more wide use of a spectrum of elementary LC and 
MS methods in a frame of combined LC-MS/MS. The 
study of BC proteome is directed on profiling of various 
biologic materials and is aimed at the improvement 
of prophylaxis, screening, diagnostics, prognosis, and 
therapy. A large pool of proteins of mammary gland 
tumors and BC-associated proteins from body fluids 
have been already identified, and in part they were 
validated. The progress of validation methods is helpful 
in more efficient application of BC biomarkers in clini-
cal practice. Taken together, the results of proteomics 
studies demonstrate an integrated interaction of the 
data and “omics” sources with the systemic approach 
for assessment of functions of biomolecules in various 
pathologies and BC in particular.
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